# A Study to Describe the Switching From a First- or Second-line Disease Modifying Therapy (DMT) to Ozanimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)

> **NCT05658601** · — · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 104 (actual)

## Conditions studied

- Multiple Sclerosis, Relapsing-Remitting

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT05658601
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2023-07-14
- **Primary completion:** 2025-07-03
- **Final completion:** 2025-07-03
- **Target enrollment:** 104 (ACTUAL)
- **Last updated:** 2025-10-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05658601

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05658601, "A Study to Describe the Switching From a First- or Second-line Disease Modifying Therapy (DMT) to Ozanimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT05658601. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*